Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

54 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-30

Study Completion Date

2019-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This proof-of-concept study is designed as a randomized, double-blind, placebo-controlled study comparing ubenimex at 150 mg, 3 times daily (total daily dose of 450 mg) with placebo for 6 months treatment period in patients with leg lymphedema.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Shock Wave Therapy for Lower Limb Lymphedema

NCT06454734

Lymphedema, Lower Limb

RECRUITING NA

Clinical Evaluation of a Device for Treatment of Lymphedema of the Upper Extremity

NCT06407791

Lymphedema Lymphedema Arm Lymphedema of Upper Arm

COMPLETED NA

Efficacy of Extracorporeal Shock Wave Therapy, Ultrasound and Phonophoresis Treatments in Lateral Epicondylitis

NCT05334953

Lateral Epicondylitis

COMPLETED NA

Lateral Epicondylitis Extracorporeal Shock Wave Therapy, Ultrasound Iontophoresis

NCT06189521

Lateral Epicondylitis

COMPLETED NA

Treatment of Lymphedema: Application of the Kinesio Taping

NCT00155220

Lymphedema

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Leukotriene B4 (LTB4) inhibits lymphangiogenesis in the mouse tail model of lymphedema and is elevated in tissue in patients with lymphedema. Ubenimex is an inhibitor of leukotriene A4 hydrolase (LTA4H), the biosynthetic enzyme for LTB4. This proof-of-concept study is designed as a randomized, double-blind, placebo-controlled study comparing ubenimex at 150 mg, 3 times daily (total daily dose of 450 mg) with placebo for 6 months treatment period in patients with leg lymphedema. The primary objectives for the study are:

* To evaluate the efficacy of ubenimex in patients with leg lymphedema
* To evaluate the safety and tolerability of ubenimex in patients with leg lymphedema

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphedema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ubenimex

ubenimex capsules 150 mg three times a day (TID), administered orally for a total of 24 weeks.

Group Type EXPERIMENTAL

ubenimex

Intervention Type DRUG

placebo

matched placebo capsules TID, administered orally for a total of 24 weeks

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ubenimex

Intervention Type DRUG

placebo

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

UBX

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Has a diagnosis of secondary leg lymphedema, based on a positive lymphoscintigraphy (LSG) study of the affected leg OR has a diagnosis of primary lymphedema not of congenital onset affecting one or both lower limbs, based on positive LSG.
2. Swelling of at least 1 leg not completely reversed by leg elevation or compression.
3. Stage II or greater lymphedema, based on the International Society of Lymphology (ISL) staging system.
4. Completion of a full course of complete decongestive therapy (CDT).
5. Stable limb volume (within 10% during screening for worse/affected leg) .
6. If patient has had a lymphatic vascularization procedure (lymphovenous bypass or lymph node transfer) or liposuction for lymphedema in the affected limb, then procedure must have been performed at least 1 year (12 months) prior to Screening AND affected limb must be clinically stable over the 3 months prior to Screening AND significant residual disease must be present.
7. Ambulatory status (use of a walking aid is permitted).
8. Agree to use a medically acceptable method of contraception, if the possibility of conception exists.

Exclusion Criteria

Exclusions Based on Lymphedema:

1. A diagnosis of primary lymphedema with congenital onset. Primary lymphedema is defined as lymphedema with onset prior to or without an inciting event (e.g, surgery, trauma, radiation)
2. Occurrence of significant lymphedema of another body part that is not the lower limb (e.g, upper extremity, trunk, head and neck, genitalia).
3. Lymphedema involving all four limbs
4. Recent initiation of, or intention to initiate CDT or maintenance physiotherapy for lymphedema.

Exclusions Based on Other Medical Conditions
5. Deep venous thrombosis in either lower limb or systemic anticoagulation within 6 months
6. Other medical condition that could lead to acute or chronic leg edema.
7. Other medical condition that could result in symptoms overlapping those of lymphedema in the affected leg.
8. History of clotting disorder (hypercoagulable state).
9. Chronic (persistent) infection in either lower limb.
10. Cellulitis or other infection in either lower limb or use of antibiotics for cellulitis within 3 months prior to screening.
11. Other unstable or severe medical condition requiring active management and/or likely to decompensate/require active management within the next year
12. Current evidence of malignancy.
13. History of malignancy within the previous 3 years, except for nonmelanoma skin cancer or cervical carcinoma in situ treated with curative intent.
14. Currently receiving chemotherapy or radiation therapy.
15. Life expectancy \< 2 years for any reason.
16. Pregnancy or nursing.
17. Substance abuse (such as alcohol or drug abuse) within 6 months prior to screening.

Exclusions Based on Concurrent Medication Use
18. Regular concurrent use or regular use within 6 months before screening of another leukotriene pathway inhibitor.
19. Concurrent antibiotic use.
20. Concurrent use of any agent active on the sphingosine-1-phosphate (S1P) pathway.
21. Concurrent use of unapproved (including herbal) treatments for lymphedema.

Exclusions Based on Laboratory Values
22. Significant or chronic renal insufficiency or requires dialytic support.
23. Hepatic dysfunction.
24. Absolute neutrophil count \<1500 mm3 at screening.
25. Hemoglobin concentration \<9 g/dL at screening.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No